Critical evaluation of vinflunine in the treatment of refractory metastatic urothelial carcinoma.
Urothelial carcinoma (UC) accounts for 5% to 10% of malignancies in men in Europe and the United States. For locally advanced or metastatic disease, there are two standard firstline chemotherapy regimens: MVAC (methotrexate, vinblastine, doxorubicin, cisplatin) and gemcitabine/cisplatin. For refract...
المؤلفون الرئيسيون: | Morel, A, Talbot, D |
---|---|
التنسيق: | Journal article |
اللغة: | English |
منشور في: |
Dove Medical Press Ltd.
2010
|
مواد مشابهة
-
Second line therapy for metastatic urothelial carcinoma. Clinical case of vinflunine use
حسب: A. A. Gritskevich, وآخرون
منشور في: (2022-06-01) -
From clinical trials to the front line: Vinflunine for Treatment of UrothelialCell Carcinoma at the National Cancer Institute of Naples
حسب: GAETANO eFACCHINI, وآخرون
منشور في: (2016-05-01) -
Vinflunine in the treatment of bladder cancer
حسب: Mark Bachner, وآخرون
منشور في: (2008-11-01) -
A Prospective Study of I.V. Vinflunine in the Treatment of Patients with Advanced or Metastatic Urothelial Carcinoma after Failure of a Platinum-containing Regimen and Biomarker Correlates
حسب: Fatma M.A. Abouelkasem, وآخرون
منشور في: (2022-08-01) -
Real-life clinical practice results with vinflunine in patients with relapsed platinum-treated metastatic urothelial carcinoma: an Italian multicenter study (MOVIE-GOIRC 01–2014)
حسب: Rodolfo Passalacqua, وآخرون
منشور في: (2017-07-01)